Cardiovascular outcome studies with novel antidiabetes agents: Scientific and operational considerations

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Hirshberg, Boaz ^a   Katz, Arie ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEGLITAZAR; ALOGLIPTIN; ANTIDIABETIC AGENT; CANAGLIFLOZIN; EXENDIN 4; FENOFIBRATE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR OUTCOME STUDY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFECT; DRUG SAFETY; GLYCEMIC CONTROL; GOVERNMENT REGULATION; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INFORMATION PROCESSING; MISSING DATA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PATIENT ATTITUDE; PATIENT RETENTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; STUDY DESIGN; TREATMENT WITHDRAWAL;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; PROGNOSIS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84891760955     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2041     Document Type: Article

References (33)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
3. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363: 233-244
4. American Diabetes Association. Standards of medical care in diabetesd2010. Diabetes Care 2010;33(Suppl. 1):S11-S61
5. Center for Drug Evaluation and Research. Guidance for Industry Diabetes Mellitus: Evaluating Cardiovascular Risk in New An-tidiabetic Therapies to Treat Type 2 Diabetes. 2008
6. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
7. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
8. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162:818.e6-825.e6
9. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367: 319-328
10. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-1708
11. Irony I. Guidance for Industry Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Center for Drug Evaluation and Research, Rockville, MD, 2008
12. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care 2011;34(Suppl. 2):S101-S106
13. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin J, Bluhmki E, Schlosser A, Neubacher D, Patel S, Johansen OE, Woerle H. Rationale and design of the CAROLINA Trial: An active comparator CARdiOvascular outcome study of the DPP-4 inhibitor LINAgliptin in patients with type 2 diabetes at high cardiovascular risk (Abstract). Diabetes 2011;60 (Suppl. 1):A303
14. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94:410-415
15. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
16. Parks M. Summary review: linagliptin. CDER 201280 Orig1s000, 2011. Available from http://www. accessdata. fda.gov/drugsatfda- docs/nda/2011/ 201280Orig1s000SumR. pdf. Accessed 1 November 2012
17. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367:1355-1360
18. Keech A, Simes RJ, Barter P, et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
19. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglita-zone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135
20. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2-TIMI 51 Investigators. Ri-varoxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19
21. Nainggolan L. FDA refuses ACS indication for rivaroxabandfor now [article online], 2012. Available from http://www.theheart.org/article/1418783.do. Accessed 15 November 2012
22. O'Neill RT, Temple R. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther 2012;91:550-554
23. Mitka M. Changes in access to death data may impede medical research [article online], 2012. Available from http://newsatjama.jama.com/2011/10/19/ changes-in-access-to-death-data-may-impede-medical-research/. Accessed 15 November 2012
24. Shiwaku K, Anuurad E, Enkhmaa B, Kitajima K, Yamane Y. Appropriate BMI for Asian populations. Lancet 2004;363:1077
25. Expert Consultation WHO; WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163
26. Danaei G, Finucane MM, Lu Y, et al.; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2z7 million participants. Lancet 2011;378:31-40
27. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009;25:705-716
28. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyper-glycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
29. Hicks KA, Hung HM, Mahaffey KW, et al. Standardized definitions for end point events in cardiovascular trials. CDISC 2010
30. Committee for Medicinal Products for Human Use. Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Melli-tus. London, European Medicines Society, 2012
31. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutidedthe FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-777
32. Pharmaceutical and Food Safety Bureau. Guideline for Clinical Evaluation of Oral Hypoglycemic Agents. 2010
33. Nathan DM. Finding new treatments for diabetesdhow many, how fast⋯ how good? N Engl J Med 2007;356:437-440